Navigation Links
Parkinson’s Drug Linked to Gamblin

A new study finds an unusual side effect from drug therapy in some Parkinson’s patients. Certain dopamine agonists show signs of causing some patients to become excessive gamblers.
Dopamine is a chemical substance that is produced in the brain that allows people to have smooth movements. Parkinson’s patients have a severe shortage of dopamine. Drug therapies for Parkinson’s focus on increasing dopamine. //Researchers at Muhammad Ali Parkinson Research Center in Phoenix conducted a study to see if excessive gambling could be a side effect of one drug therapy.

For the study, researchers looked at the data of 1,884 patients who were seen at the center during one year. They found nine patients had gambling problems. All nine were taking levodopa and a dopamine agonist. In the brain levodopa is transformed into dopamine. The other study drug activates the dopamine receptor in the brain.

None of the patients had a previous history of gambling. Researchers say seven of the patients started gambling within one month after their dosage of the dopamine agonist was increased. All of the patients were in the advanced stages of the disease. Study authors say the gambling was severe enough to cause financial problems and two of the patients lost more than $60,000.

Researchers say after a caretaker or family member noticed the gambling problem, the patients’ drug therapies were changed. For most of the patients the new treatment plan fixed the problem. Researchers feel higher dosages of dopamine agonist may be to blame for excessive gambling. They add while the risk of this side effect is small, doctors need to inform patients about this unusual side effct.
'"/>




Page: 1

Related medicine news :

1. NPIL withdraws Parkinson’s dru
2. Delaying Parkinson’s Diseas
3. New Drug For Parkinson’s Disease With Less Side Effect
4. Embryonic Cells Might Prevent Parkinson’s Disease From Worsenin
5. Magnetic Stimulation For Parkinson’s Diseas
6. Exercising regularly can reduce the risk of Parkinson’s diseas
7. Fetal Cell Transplant Found To Improve Movement In Patients With Parkinson’s Disease
8. New Medicine For Parkinson’s disease
9. A New Addition Could Help Patients With Parkinson’s Disease
10. Milk intake increases the risk of Parkinson’s disease in midlife
11. Ibuprofen to lower risk of Parkinson’s diseas
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Parkinson Drug Linked Gamblin

(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...sure levels that tend to be slightly elevated but ...d high-normal--are at increased risk for suffering...aken in two numbers. The systolic value i.e., the ...resents the pressure in the heart during contracti...
...trol pills should be mindful of the possible inter...ions recommended by the Federal Centers for Diseas...he CDC recently recommended that antibiotic and an...ine, and penicillin, be used to treat those believ...
...through, a team of scientists have successfully tr...e to the diseased one, bringing light to the peopl...ning the current excitement about stem cells, in a...uch as chemical burns, allergic reactions to drug ...
...n acrylic cement mend fractures linked to osteopor...the University of California have been looking at ...res in 90 elderly patients with osteoporosis. They...a - a procedure formerly done during surgery. Two ...
Other Medicine News:
(Date:9/3/2008)...ease Awareness Month, CHARLOTTESVILLE, Va., Sept....a clinical-stage drug-development company commerci...al needs, announced today that it has begun,to enr... lead drug,candidate trans sodium crocetinate (TSC...altrials.gov Website, is investigating TSC as a tr...
(Date:9/3/2008)...- Panacea Pharmaceuticals,Inc. today announced th...g,antibodies against human aspartyl (asparaginyl) ...r biomarker and therapeutic target. These antibodi...husetts Institute of,Technology (MIT) and Panacea ... development of human cancer diagnostics and thera...
(Date:9/3/2008)...lans with FDA, PRINCETON, N.J., Sept. 3 /PRNewswi...hat it successfully completed two key clinical tri...ative low-dose, once-weekly,contraceptive patch, ...t,code AG-200-15. The Phase 2b safety and efficacy...ulation suppression, cycle control and safety. The...
(Date:9/3/2008)...nce Pycnogenol(R) Lowers Joint, Pain, Symptoms; Ma...ation of the Extract, ...to the Center for,Disease Control (CDC), osteoarth...e rise. A new study published in the August journa... bark extract from the French maritime pine,tree, ...
Breaking Medicine Technology:Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Romark Laboratories Completes Enrollment in U S Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non Responders 2156 1Romark Laboratories Completes Enrollment in U S Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non Responders 2156 2Romark Laboratories Completes Enrollment in U S Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non Responders 2156 3Iraq war service 3A A risk factor for bronchiolitis 3F 19967 1Iraq war service 3A A risk factor for bronchiolitis 3F 19967 2Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 1Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 2Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 3Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 4Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 5New Anticoagulation Management Software Helps Clinics Enhance Efficiency and Improve Patient Safety 19962 1New Anticoagulation Management Software Helps Clinics Enhance Efficiency and Improve Patient Safety 19962 2
... WIRE)--May 1, 2007 - Teva,Pharmaceutical Industri... data from a 36-week, randomized, double-blind,pl... an oral 0.6 mg,dose of laquinimod given daily sig...) disease activity by 38 percent in RRMS,patients ...avorable,trend towards reducing annual relapse rat...
...isease Activity as Measured,by MRI and Relapse --...nc.,(NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BII...inical study of Rituxan®,(rituximab) in patien...MS) were presented today at the American Academy o... is a therapeutic antibody,that targets and select...
Other Medicine Technology:Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 2Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 3Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 4Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 5Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 6Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6
...ic stools come with five legs for extra stability....ical travel 6"). 2" ball bearing swivel hard rubbe... upholstery, available in black vinyl as standard,... a contoured, padded, upholstered backrest, with v...
Anterior Stromal Puncture Cannula, 25 g. For treatment of recurrent corneal erosion. Overall length 24 mm. 5/box.
Viscoelastic Cannula, 27 g. Angled. 7 mm angled tip cannula with unique hub that facilitates flow of viscoelastic material. Overall length 23 mm. 5/box.
Anterior Chamber Needle, 30 g. Angled. 5 mm angled tip. Overall length 20 mm. 5/box.
Medicine Products: